ATAI
ATAI Life Sciences N.V.
Company Overview
| Mkt Cap | $1.43B | Price | $3.80 |
| Volume | 3.86M | Change | +3.83% |
| P/E Ratio | -9.6 | Open | $3.65 |
| Revenue | $308.0K | Prev Close | $3.66 |
| Net Income | $-149.3M | 52W Range | $1.15 - $6.75 |
| Div Yield | N/A | Target | $12.13 |
| Overall | 45 | Value | 40 |
| Quality | -- | Technical | 50 |
No chart data available
About ATAI Life Sciences N.V.
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, and other mental health disorders. The company's product candidates include COMP360, BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, a transmucosal film in Phase 2 clinical study; and ELE-101, a serotonergic psychedelic for the treatment of treatment resistant depression. It also EMP-01, an oral formulation of an R-MDMA that Is in phase 2 clinical study; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, the company offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, for the treatment of generalize anxiety disorder. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Latest News
ATAI Life Sciences Files Prospectus for Share Resale
ATAI Life Sciences Approves Beckley Psytech Acquisition
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATAI | $3.80 | +3.8% | 3.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |